Harmony Biosciences' Product Costs Hit 30.0% Of Revenue As New Royalties Kick In

Cost of product sold rose from 24.9% a year earlier, and $35.0 million in milestone payments come due in the fourth quarter.

Share
Harmony Biosciences' Product Costs Hit 30.0% Of Revenue As New Royalties Kick In

Harmony Biosciences, which sells the narcolepsy drug WAKIX, saw cost of product sold climb to 30.0% of net product revenue in the third quarter, up from 24.9% a year earlier, its 10-Q filed Wednesday shows. The company blames new royalties under its Novitium license, and $35.0 million of milestone payments are due in the fourth quarter.

Royalties Squeeze The Margin

Net product revenue rose 12.3% to $268.9 million, helped by a 7.5% increase in units shipped and a 7% price increase, partly offset by higher rebates of about 2.0%. Cost of product sold rose 35.3% to $80.7 million, faster than sales.

The filing says the jump in the cost ratio was driven by new royalties under the Novitium License Agreement. The prior quarter's 10-Q put the ratio at 24.2% for the three months ended June 30, 2026. Royalties recognized in cost of sales were $78.3 million in the quarter, against $57.3 million a year earlier, and the same $78.3 million sits in accrued expenses, up from $65.8 million at year-end.

Operating income fell to $54.2 million from $65.5 million a year earlier. Net income slipped to $48.2 million, or $0.81 per diluted share, from $50.9 million, or $0.87. The company's earnings release put the decline on higher milestone charges and new MSN royalty charges, and said 400 net patient additions took the average to 9,350.

Licenses That Extend The Franchise

Harmony is a neuroscience company focused on rare neurological diseases. WAKIX is a once-daily tablet approved for excessive daytime sleepiness and cataplexy in narcolepsy, and it is the company's only commercial product.

In early 2026 it signed license deals with Novitium and MSN to develop an amorphous formulation of pitolisant, WAKIX's active ingredient, for CNS conditions outside sleep. Novitium carries an upfront fee of $15.0 million and low single-digit royalties; MSN carried $17.0 million upfront and low single-digit royalties on future products.

In-process research and development charges reached $57.0 million for the nine months, against $30.0 million a year earlier. The third quarter alone included a $25.0 million MSN milestone, triggered in September when the patent office approved MSN's pending licensed patents.

Payments Due And Court Dates

Harmony expects to pay the $25.0 million MSN milestone in the fourth quarter. A further $10.0 million milestone under the Novitium agreement, reached in October, is also expected to be paid and expensed in the fourth quarter.

The company held $1,051.6 million in cash and investments and $150.0 million of debt at September 30. It reiterated full-year WAKIX revenue guidance of $1.0 billion to $1.04 billion.

In the lawsuit Harmony and Novitium filed against AET and Sandoz over the amorphous-form patent, a preliminary injunction hearing is set for January 26, 2027, with a decision expected by February 14, 2027. The FDA's target date for the Pitolisant GR application is April 1, 2027. Separately, an 8-K/A shows Peter Anastasiou, now chief operating officer, becomes CEO on January 1, 2027, succeeding Jeffrey Dayno, who retires December 31, 2026.

The company says the Novitium royalties drove the margin squeeze, and the January 26, 2027 injunction hearing is the next court date in the amorphous-patent fight.

Sources

More on Harmony Biosciences

All Harmony Biosciences (HRMY) coverage →